Skip to main content


First Annual Conference on CNS Clinical Trials,
Co-Sponsored by SNO and ASCO

October 1-2, 2021
A Virtual Conference  

Abstract submission deadline has passed.  

Paid Registrant Access

View Program At A Glance

View Full Program

Announcing the First Annual Conference on CNS Clinical Trials, Co-Sponsored by SNO and ASCO, being held virtually Friday, October 1 - Saturday, October 2, 2021, starting at 11:00am Eastern. The goal of this annual conference is to provide a deeper dive into the area of neuro-oncology clinical trials to understand how we can make more significant improvements in survival and quality of life of patients with primary and metastatic cancers of the central nervous system.

This collaborative conference will address the needs of patients with glioblastoma and intracranial malignancy in general, both primary and secondary, and stimulate clinical research in these areas of great unmet clinical need. Research advocating new approaches, out of the box ideas and reforms in the area of neuro-oncology clinical trials will be presented and discussed. The structure will provide a forum that cuts across a large breadth of disciplines and emphasizes aspects of clinical trial design, statistics and interpretation of trial outcomes to develop a better understanding of why numerous glioblastoma and other neuro-oncology clinical trials do not achieve their ultimate objective of prolonging survival of patients and other meaningful clinical measures. In addition, it will provide a forum that promotes collaboration and cross-fertilization of novel ideas between those invested in the care of patients with primary and secondary malignancies of the CNS.

Learning Objectives

  • Explain the consensus treatment of glioblastoma from an overview of clinical trials vs standard of care on the outcomes of overall survival.
  • Identify strategies to integrate the inclusion and reporting of quality-of-life endpoints in clinical trials of cancer drugs.
  • Explain the clinical trial landscape for GBM as it pertains to optimally evaluating new therapies and biomarkers.
  • Describe the use of real-world evidence and external control arms in clinical trials for primary and metastatic cancers of the CNS. 
  • Compare novel imaging platforms that assess both response assessment and differentiation of tumor vs treatment effect, and their potential therapeutic applications for patients with primary and metastatic cancers of the CNS.
    This Conference is a CME activity.  
Registration is now open.  

Who should attend

Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, and Patient Advocates.

Abstract Submission

The abstract submission deadline has passed. The conference organizers welcomed the submission of original research on the following topics:
Systemic Therapeutics (e.g. Targeted, ADC, Cytotoxic
Local Therapies (e.g. Surgery, Radiation, LITT, others)
Immunotherapy (e.g. Car-T cell, Oncolytic Viruses)
Clinical Research Methods (e.g. Trial Design, Molecular Correlatives, Big Data)
Supportive Care and Survivorship (e.g. Neurocognition, QoL, Palliative Care)
Neuroimaging (Diagnostic and Therapeutic Applications/Endpoints in Trials)
Accepted abstracts will be published and indexed in Neuro-Oncology Advances.
Program Chairs
Program Committee Co-Chairs
Carey Anders, Duke Cancer Institute
Gelareh Zadeh, University Health Network, Toronto Western Hospital/University of Toronto

Program Committee Co-Chairs Elect
Priscilla Brastianos, Massachusetts General Hospital, Harvard Medical School
Mustafa Khasraw, Duke University

Programming Committee
Evanthia Galanis, Mayo Clinic
Sarah Goldberg, Yale School of Medicine
Sara Hurvitz, University of California, Los Angeles; Jonnson Comprehensive Cancer Center
Rupesh Kotecha, Miami Cancer Institute
Emilie Le Rhun, University Hospital Zurich, Switzerland
Nancy Lin, Dana Farber Cancer Institute
Alireza Mansouri, Penn State Cancer Institute
Minesh Mehta, Miami Cancer Institute
Michael Platten, University Medical Center Mannheim   
Mei-Yin C. Polley, University of Chicago
Solmaz Sahebjam
Hussein Tawbi, University of Texas MD Anderson Cancer Center

For a full list of invited speakers and panelists, click here.  

For a full list of moderators, click here.  

CME Credits
This Conference is a CME activity.  For full CME details, click here

If you are interested in having a presence at the upcoming Clinical Trials Conference, please contact  

SNO would like to thank Novocure and Seagen for its support through an unrestricted medical education grant of this conference.